Gemcitabine in the treatment of bladder cancer

Christopher W. Ryan, Nicholas J. Vogelzang

Research output: Contribution to journalReview articlepeer-review

2 Scopus citations

Abstract

New agents are available for the treatment of metastatic transitional cell carcinoma of the bladder. In the US, the combination of methotrexate, vinblastine, doxorubicin and cisplatin (M-VAC) remains the standard chemotherapy regimen for advanced bladder cancer. Gemcitabine (2′,2″-difluorodeoxycytidine [dFdCD is a relatively new agent with a favourable toxicity profile that has demonstrated activity against a number of solid tumours in both preclinical and clinical studies. Single-agent gemcitabine has shown activity in bladder cancer in both pretreated and chemotherapy-naïve patients. The combination of gemcitabine plus cisplatin is a regimen with significant activity and moderate toxicity in bladder cancer patients. A randomised trial of gemcitabine plus cisplatin versus M-VAC has completed accrual but has not yet been reported. New combination studies of gemcitabine with other chemotherapy agents, including the taxanes, are ongoing. 2000

Original languageEnglish (US)
Pages (from-to)547-553
Number of pages7
JournalExpert Opinion on Pharmacotherapy
Volume1
Issue number3
DOIs
StatePublished - Mar 2000
Externally publishedYes

Keywords

  • Antimetabolites
  • Bladder cancer
  • Cisplatin
  • Clinical trials
  • Gemcitabine
  • Transitional cell carcinoma

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)

Fingerprint Dive into the research topics of 'Gemcitabine in the treatment of bladder cancer'. Together they form a unique fingerprint.

Cite this